GUBRA Stock Overview
Operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gubra A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.328.00 |
| 52 Week High | kr.359.00 |
| 52 Week Low | kr.83.45 |
| Beta | 0 |
| 1 Month Change | 9.33% |
| 3 Month Change | 56.19% |
| 1 Year Change | 241.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 198.18% |
Recent News & Updates
Shareholder Returns
| GUBRA | DK Life Sciences | DK Market | |
|---|---|---|---|
| 7D | 5.5% | -4.0% | 0.1% |
| 1Y | 241.7% | -19.4% | 34.2% |
Return vs Industry: GUBRA exceeded the Danish Life Sciences industry which returned -19.4% over the past year.
Return vs Market: GUBRA exceeded the Danish Market which returned 34.2% over the past year.
Price Volatility
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 11.8% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in DK Market | 9.9% |
| 10% least volatile stocks in DK Market | 2.9% |
Stable Share Price: GUBRA's share price has been volatile over the past 3 months.
Volatility Over Time: GUBRA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 220 | Henrik Blou | www.gubra.dk |
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging.
Gubra A/S Fundamentals Summary
| GUBRA fundamental statistics | |
|---|---|
| Market cap | kr.5.34b |
| Earnings (TTM) | -kr.44.52m |
| Revenue (TTM) | kr.205.01m |
26.1x
P/S Ratio-120.0x
P/E RatioIs GUBRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUBRA income statement (TTM) | |
|---|---|
| Revenue | kr.205.01m |
| Cost of Revenue | kr.90.07m |
| Gross Profit | kr.114.94m |
| Other Expenses | kr.159.46m |
| Earnings | -kr.44.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -2.73 |
| Gross Margin | 56.07% |
| Net Profit Margin | -21.72% |
| Debt/Equity Ratio | 0% |
How did GUBRA perform over the long term?
See historical performance and comparison